These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 22574518)
1. Development of chromatographic method for determination of drugs reducing cholesterol level. Kublin E; Malanowicz E; Kaczmarska-Graczyk B; Mazurek AP Acta Pol Pharm; 2012; 69(1):139-43. PubMed ID: 22574518 [No Abstract] [Full Text] [Related]
2. DEVELOPMENT OF CHROMATOGRAPHIC METHOD FOR DETERMINATION OF DRUGS REDUCING CHOLESTEROL LEVEL--STATINS AND EZETIMIBE. Kublin E; Malanowicz E; Kaczmarska-Graczyk B; Czerwińska K; Wyszomirska E; Mazurek AP Acta Pol Pharm; 2015; 72(3):429-37. PubMed ID: 26642651 [TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins. Waldron J; Webster C Ann Clin Biochem; 2011 May; 48(Pt 3):223-32. PubMed ID: 21355014 [TBL] [Abstract][Full Text] [Related]
4. Determination by chromatographic methods of selected medicines reducing the level of cholesterol. Kublin E; Kaczmarska-Graczyk B; Mazurek AP Acta Pol Pharm; 2006; 63(5):404-7. PubMed ID: 17357595 [No Abstract] [Full Text] [Related]
5. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Shah PK Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180 [TBL] [Abstract][Full Text] [Related]
7. Changing face of dyslipidemia therapy. Banerjee AK Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305 [No Abstract] [Full Text] [Related]
8. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. Schrott HG; Knapp H; Davila M; Shurzinske L; Black D Am Heart J; 2000 Aug; 140(2):249-52. PubMed ID: 10925339 [TBL] [Abstract][Full Text] [Related]
9. Update on statins and other lipid-lowering drugs. Miller CA Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910 [No Abstract] [Full Text] [Related]
10. Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol? Rana JS; Boekholdt SM Curr Opin Cardiol; 2010 Nov; 25(6):622-6. PubMed ID: 20852414 [TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]. Carmena R Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284 [No Abstract] [Full Text] [Related]
12. [Hemorheological aspects of hyperlipidemia]. Elishkewitch K; Shapira I; Berliner S Harefuah; 2001 May; 140(5):435-6. PubMed ID: 11419070 [No Abstract] [Full Text] [Related]
13. The power of statins: aggressive lipid lowering. Jones PH Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597 [TBL] [Abstract][Full Text] [Related]
14. Atorvastatin: a new agent for hyperlipidemia. Kupecz D Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876 [No Abstract] [Full Text] [Related]
15. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)]. Motz W MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487 [No Abstract] [Full Text] [Related]
16. Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment. Fentoğlu O; Sözen T; Oz SG; Kale B; Sönmez Y; Tonguç MO; Gürgan CA; Aykaç Y; Kirzioğlu FY Oral Dis; 2010 Oct; 16(7):648-54. PubMed ID: 20412449 [TBL] [Abstract][Full Text] [Related]